Innocoll is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet some of today’s most important healthcare challenges. Our current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management.
Postsurgical Pain Management Product Currently in Development
XARACOLL® is a novel collagen-matrix implant in late-stage development designed to deliver bupivacaine HCl to the surgical site.
News & Media
- Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL® for the Management of Postsurgical Pain
- Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL® for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery
- Innocoll Holdings Limited Appoints Richard Fante as Chief Executive Officer